Business Context and Reporting Period
Company: Genmab A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of May 2025
Filing Date: May 8, 2025
Principal Executive Offices: Carl Jacobsens Vej 30, 2500 Valby, Denmark
This filing serves as a cover document incorporating by reference an Interim Report dated May 8, 2025 (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific financial data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced Exhibit 99.1, which is not included in the input content.
Material Changes
No material changes versus the prior comparable period are described in the provided text. The document serves solely to notify the SEC of the filing of the interim report.
Guidance, Outlook, and Risks
The provided text contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. Such information is expected to be detailed in the incorporated Interim Report (Exhibit 99.1).
Investor Verification Checklist
- Verify the contents of Exhibit 99.1 (Interim Report Dated May 8, 2025) for actual financial performance data.
- Confirm the incorporation by reference status in Genmab A/S's registration statements on Form S-8 (File Nos. 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876).
- Review the full interim report for any updates on clinical trials, regulatory approvals, or partnership milestones typical for a biopharmaceutical issuer.